December 2022 in “Small methods” This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.
9 citations
,
June 2025 in “Frontiers in Pharmacology” This review highlights recent advancements in microneedle technology, noting its ability to enhance transdermal drug delivery, biosensing, cancer treatment, and skin disease repair, while emphasizing its potential for improving patient compliance and reducing side effects.
March 2026 in “Bioconjugate Chemistry” This review highlights the potential of peptide-based PROTACs (pPROTACs) in expanding the target range of protein degraders beyond small-molecule limitations, particularly for undruggable proteins, by utilizing advances in design, conjugation, and bioPROTAC technology.
4 citations
,
May 2024 in “Biomolecules” This study examined connections between bioelements like Zn, Cu, and Mn in serum and bone tissue and hormone concentrations in men with and without erectile dysfunction, highlighting potential relationships that may help explain ED's etiology.
January 2026 in “Dermatologic Therapy” This review indicates that while microneedling shows potential for managing androgenetic alopecia, particularly in combination with other treatments, the existing evidence is of low to moderate quality, and more robust trials are needed to confirm its clinical efficacy and safety.